Search for Joe Jimenez and
  1. July 17, 2014

    Novartis maintains forecasts despite weak quarter

    Novartis confirmed its full-year profit and revenue forecasts, despite weaker than expected second-quarter results and the...

  2. April 24, 2014

    Novartis profits boosted by sales in emerging markets

    Novartis posted a 23 per cent jump in net profits in the first quarter, thanks to the sale of one of its diagnostics units,...

  1. April 22, 2014

    GSK chief quick to distance Novartis deal from megamerger mania

    Another day, another big pharma deal. Novartis and GlaxoSmithKline became the latest companies to join the industry’s...

  2. April 22, 2014

    Novartis chief Joe Jimenez makes biggest move at group

    The multibillion-dollar reshaping of Novartis announced on Tuesday is easily the most significant move that Joe Jimenez, the...

  3. April 22, 2014

    Novartis buys GSK business for up to $16bn in restructuring

    Novartis and GlaxoSmithKline have agreed to swap a series of assets in a multibillion-dollar deal that will reshape two of...

  4. April 2, 2014

    Big pharma’s rise in China not held back by scandals

    When Chinese authorities accused GlaxoSmithKline last summer of being the “godfather” at the centre of a network of...

  5. March 10, 2014

    Novartis restructure marks break from expansion

    It is four years since Joe Jimenez took over as chief executive of Novartis. But, in some ways, it feels as if he is only...

  6. February 16, 2014

    Novartis puts pressure on India over patent abuse

    Novartis has urged US and European governments to “apply pressure” on India to respect intellectual property and warned New...

  7. February 13, 2014

    Recent votes call into question Swiss hospitality to business

    Few countries have been more hospitable to business than Switzerland. Its stable laws and favourable tax regime have proved...

  8. January 29, 2014

    Novartis considers future of $14bn Roche stake

    Novartis’s $14bn stake in its local rival Roche is one of the assets it is scrutinising as part of a broader review of its...

  9. December 8, 2013

    Change without sour grapes

    When Jörg Reinhardt rejoined Novartis in August to take up his new role as chairman of the Swiss pharmaceutical group, he...

  10. November 11, 2013

    Novartis agrees $1.7bn sale of blood diagnostics unit to Grifols

    Novartis has agreed to sell its blood diagnostics unit to the Spanish healthcare group Grifols for $1.7bn, in the first of a...

  11. June 17, 2013

    Novartis pioneers health project in rural China

    China may be one of the world’s largest markets for companies from Rolls-Royce to Rolex, but beneath that veneer of wealth...

  12. February 24, 2013

    Novartis’ U-turn marks a crossroads

    Daniel Vasella may have struggled at first to speak English when he was sent to the US on his first pharmaceutical industry...

  13. January 23, 2013

    Vasella to step down as Novartis chairman

    Shares jumped sharply at Novartis on anticipation of a shift in strategy at the Swiss healthcare group, following the abrupt...

  14. July 19, 2012

    Novartis offsets effects of patent expiry

    Novartis reported second-quarter net income unchanged at $2.7bn and maintained existing full-year 2012 guidance, despite...

  15. April 26, 2012

    Simon Lowth, interim CEO AstraZeneca

    Simon Lowth’s appointment as interim chief executive of AstraZeneca puts him in a strong position as the long-term successor...

  16. February 5, 2012

    Pharma seeks to ease pain of euro crisis

    With Greece and Spain struggling to repay billions of euros in outstanding debts to the healthcare sector as the eurozone...

  17. January 25, 2012

    Novartis upbeat despite end of Diovan patent

    Novartis forecast it would maintain sales and suffer only potentially slightly lower operating profits this year, despite...

  18. October 25, 2011

    Novartis to cut 10% of Swiss workforce

    Novartis will cut its core Swiss workforce by almost 10 per cent, in the latest attempt by a top pharmaceuticals group to...

  19. June 27, 2011

    China: Pharma heads east for profit

    After 30 years of economic reform in China, the growing middle class is discovering there is more to life than working – and...

  20. April 19, 2011

    Novartis profit hit by costs of Alcon buy-out

    Novartis boosted sales in the first quarter, but the Swiss pharmaceuticals group’s net profits fell because of higher...

  21. March 16, 2011

    Novartis plans to close drugs factory

    Novartis has dealt a fresh blow to the UK’s historical strength in the pharmaceutical sector with plans to reduce...

  22. January 27, 2011

    Novartis confident despite market pressures

    Novartis remains optimistic about the current year, in spite of intensifying pricing pressure in many markets as stretched...

  23. December 15, 2010

    Novartis climbs down to clinch Alcon

    Novartis has backed down in its battle with the independent directors of Alcon by agreeing to pay an extra $1bn to buy out...

  24. November 17, 2010

    Novartis looks beyond pills in latest drive

    Novartis aims to generate a “substantial” proportion of its future drug sales from contracts directly linked to improved...

  25. November 15, 2010

    Novartis closes in on growth formula

    Novartis could be back on the takeover trail within the next four years as debt from its $50bn acquisition of Alcon falls...

  26. October 21, 2010

    Novartis results lifted by new products

    Novartis demonstrated the benefits of continuing efficiency improvements and a strong pipeline of new drugs, as the Swiss...

  27. July 15, 2010

    Novartis raises outlook on 19% profits rise

    Novartis kicked off the European pharmaceuticals reporting season on Thursday with solid rises in sales and earnings on the...

  28. June 11, 2010

    The last word: Why researchers are no longer moving from the lab to the boardroom

    Wanted: chief executive for pharmaceutical company to bring lucrative new medicines to market. Scientists need not apply....

  29. June 10, 2010

    Researchers are out of race for the top job

    Wanted: chief executive for pharmaceutical company to bring lucrative new medicines to market. Scientists need not apply....

  30. May 10, 2010

    From fast moving goods to making drugs faster

    Joe Jimenez greets his visitor in an imposing but anonymous meeting room at Novartis's Basel headquarters. The setting could...

  31. May 9, 2010

    Making drugs faster

    Joe Jimenez greets his visitor in an imposing but anonymous meeting room at Novartis’s Basel headquarters. The setting could...

  32. April 21, 2010

    Swine flu vaccine boosts Novartis

    Novartis, the Swiss pharmaceuticals group, reported a large jump in first-quarter earnings boosted by strong sales of its...

  33. April 20, 2010

    Novartis

    Joe Jimenez has a lot to be thankful for. As the new chief executive of Novartis, the Swiss pharmaceutical company, he has...

  34. April 20, 2010

    Novartis reports strong sales and earnings

    Novartis, the Swiss pharmaceuticals group, reported strong sales and earnings in the first-quarter with Joe Jimenez and Jon...

  35. January 27, 2010

    Novartis chairman Vasella to quit joint CEO role

    Daniel Vasella, the high-profile European pharmaceuticals industry executive who has steered the rise of Novartis for more...

  36. January 27, 2010

    Rise of Jimenez

    Joe Jimenez has risen fast to head a company in a foreign country and sector. Mr Jimenez, an American who graduated from...

  37. January 27, 2010

    Novartis in stealthy pursuit of change

    Daniel Vasella may be among the more youthful chief executives in the international pharmaceutical industry - but he is also...

  38. January 27, 2010

    Vasella gives up role as chief of Novartis

    Daniel Vasella, the high-profile European pharmaceuticals industry executive who has steered the rise of Novartis for more...

Search for Joe Jimenez and